SS-31 Research Guide
A mitochondria-targeted tetrapeptide (elamipretide) that binds cardiolipin. Covers the mechanism research, clinical trials and its 2025 accelerated approval.
What is SS-31?
SS-31 (elamipretide) is an aromatic-cationic tetrapeptide from the Szeto-Schiller (SS) peptide family. It penetrates cell membranes and localizes to the inner mitochondrial membrane (Szeto, 2014, Karaa et al., 2018).
Its target is cardiolipin, a phospholipid found only on the inner mitochondrial membrane, where it supports the folding of the cristae and the organization of respiratory complexes into supercomplexes (Szeto, 2014).
Research areas studied
The findings below come from cell, animal and published clinical research. They describe what studies have examined and reported, not effects of any research material.
Mechanism
SS-31 binds cardiolipin selectively through electrostatic and hydrophobic interactions. The interaction between cardiolipin and cytochrome c determines whether cytochrome c acts as an electron carrier or as a peroxidase, and the developer’s review reports that SS-31 prevents cardiolipin from converting cytochrome c into a peroxidase while protecting its electron-carrying function (Szeto, 2014).
Preclinical research
The same review summarizes animal and cell research in conditions that share cardiolipin damage and energy deficiency, and describes SS-31 as protecting mitochondrial cristae structure and supporting oxidative phosphorylation in those models (Szeto, 2014).
Clinical research
MMPOWER, a phase I/II randomized, placebo-controlled dose-escalation trial, studied 36 adults with genetically confirmed primary mitochondrial myopathy, using distance in the 6-minute walk test after 5 days as the primary measure (Karaa et al., 2018). In Barth syndrome, a genetic disorder of cardiolipin metabolism, a randomized crossover trial in 12 participants did not meet either primary endpoint in its placebo-controlled part. Improvements in walking distance and symptom scores were reported at 36 weeks in the open-label extension (Reid Thompson et al., 2021).
Regulatory status and limits of the evidence
In September 2025, elamipretide (Forzinity) received accelerated approval in the USA to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. It is in phase 3 development for dry age-related macular degeneration and mitochondrial myopathies (Shirley, 2026). Human trials are small and some key results come from open-label phases. The approval applies to the manufactured medicine for one rare disease, not to research material.
Storage and handling
Like most research peptides, SS-31 is normally supplied for laboratory use as a lyophilized (freeze-dried) powder in a sealed vial. Check the label and the batch COA for the exact form of your lot. Zero Zero Collection recommends keeping vials refrigerated at 2 to 8 ยฐC and protected from light, as stated on every product page. Let a refrigerated vial reach room temperature before opening it so moisture does not condense on the powder.
When a lab reconstitutes lyophilized material, standard practice is to add a sterile diluent such as bacteriostatic water slowly down the inside wall of the vial, then swirl gently rather than shake. The volume depends on the concentration a protocol calls for, so follow your own lab’s validated method. Label the vial with the date, keep reconstituted material refrigerated, and follow your institution’s guidance on how long a solution stays usable.
Quality and COA
Every Zero Zero Collection product page has a View COA link. Certificates of analysis come from independent third-party testing by Freedom Diagnostics and are posted on our Quality page where available. A COA reports what the testing lab measured for one specific batch, so match the lot number on your vial to the certificate. Our FAQ explains how to read a COA.
SS-31 FAQ
Is SS-31 the same as elamipretide?
Yes. Elamipretide is the nonproprietary name for SS-31, a tetrapeptide from the Szeto-Schiller peptide family.
What does SS-31 bind to?
Cardiolipin, a phospholipid found only on the inner mitochondrial membrane.
Is SS-31 approved?
The manufactured medicine Forzinity received FDA accelerated approval in September 2025 for one rare disease, Barth syndrome. Research material is not an approved medicine.
References
- Szeto HH (2014). Br J Pharmacol. PubMed 24117165
- Karaa A, Haas R, Goldstein A, et al. (2018). Neurology. PubMed 29500292
- Reid Thompson W, Hornby B, Manuel R, et al. (2021). Genet Med. PubMed 33077895
- Shirley M (2026). Drugs. PubMed 41335372
For research use only. Not for human consumption. This guide summarizes published scientific literature for laboratory research context. It is not medical advice, dosing guidance or a claim of safety or effectiveness for any use in people or animals.